JP2021529753A5 - - Google Patents
Info
- Publication number
- JP2021529753A5 JP2021529753A5 JP2020572903A JP2020572903A JP2021529753A5 JP 2021529753 A5 JP2021529753 A5 JP 2021529753A5 JP 2020572903 A JP2020572903 A JP 2020572903A JP 2020572903 A JP2020572903 A JP 2020572903A JP 2021529753 A5 JP2021529753 A5 JP 2021529753A5
- Authority
- JP
- Japan
- Prior art keywords
- macrophages
- monocytes
- activity
- target
- copy number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692463P | 2018-06-29 | 2018-06-29 | |
| US62/692,463 | 2018-06-29 | ||
| US201962810683P | 2019-02-26 | 2019-02-26 | |
| US62/810,683 | 2019-02-26 | ||
| US201962857199P | 2019-06-04 | 2019-06-04 | |
| US62/857,199 | 2019-06-04 | ||
| US201962867532P | 2019-06-27 | 2019-06-27 | |
| US62/867,532 | 2019-06-27 | ||
| PCT/US2019/039773 WO2020006385A2 (en) | 2018-06-29 | 2019-06-28 | Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529753A JP2021529753A (ja) | 2021-11-04 |
| JP2021529753A5 true JP2021529753A5 (enExample) | 2022-07-05 |
Family
ID=68985243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572903A Pending JP2021529753A (ja) | 2018-06-29 | 2019-06-28 | 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210189342A1 (enExample) |
| EP (1) | EP3813881A4 (enExample) |
| JP (1) | JP2021529753A (enExample) |
| KR (1) | KR20210040948A (enExample) |
| CN (1) | CN113164589A (enExample) |
| AU (1) | AU2019293600A1 (enExample) |
| BR (1) | BR112020026386A2 (enExample) |
| CA (1) | CA3103154A1 (enExample) |
| TW (1) | TW202023629A (enExample) |
| WO (1) | WO2020006385A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210379118A1 (en) * | 2018-10-19 | 2021-12-09 | Regenics As | Use of egg cellular extract for wound healing |
| EP3927728A2 (en) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| CA3141334A1 (en) | 2019-06-04 | 2020-12-10 | Verseau Therapeutics, Inc. | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
| KR20220042128A (ko) * | 2019-06-27 | 2022-04-04 | 베르조 테라퓨틱스, 아이엔씨. | 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도 |
| BR112021026411A2 (pt) * | 2019-06-27 | 2022-03-15 | Verseau Therapeutics Inc | Composições anti-lrrc25 e métodos para modular fenótipos inflamatórios de células mieloides e usos dos mesmos |
| WO2021091885A2 (en) | 2019-11-04 | 2021-05-14 | Alector Llc | Siglec-9 ecd fusion molecules and methods of use thereof |
| US20230058380A1 (en) * | 2019-12-30 | 2023-02-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Intrapancreatic m2 polarization of macrophages to treat type 1 diabetes |
| CA3167921A1 (en) * | 2020-01-28 | 2021-08-05 | Nanotomer, Inc. | Clathrin-chimeric antibody receptor constructs for immune cell activation therapy in vivo |
| US11642629B2 (en) * | 2020-03-20 | 2023-05-09 | Saudi Arabian Oil Company | Multi-layer composite gas separation membranes, methods for preparation, and use |
| US20230104315A1 (en) * | 2020-03-27 | 2023-04-06 | Boundless Bio, Inc. | Method of identifying extrachromosomal dna signatures |
| BR112022021104A2 (pt) | 2020-04-20 | 2022-11-29 | Duogenic Stemcells Corp | Macrófagos modificados, suas composições e seus usos |
| WO2021263115A1 (en) * | 2020-06-26 | 2021-12-30 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment |
| CN112837306B (zh) * | 2021-02-20 | 2022-11-22 | 薛竟宜 | 基于深度学习和中智理论的冠状动脉病变功能学定量方法 |
| CN113884682B (zh) * | 2021-04-30 | 2023-07-21 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 检测巨核细胞或血小板表面标志分子的产品在制备检测感染的产品中的用途 |
| US20240335500A1 (en) * | 2021-07-23 | 2024-10-10 | University Of Florida Research Foundation, Incorporated | Controlling pro-inflammatory macrophage phenotype through biofunctional hydrogel design |
| CN113897397B (zh) * | 2021-09-30 | 2024-04-02 | 中南大学 | 一种基于DNAzyme调控基因编辑的方法 |
| CN114010666B (zh) * | 2021-10-22 | 2024-05-07 | 上海交通大学 | 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用 |
| CN113913507A (zh) * | 2021-10-29 | 2022-01-11 | 温州医科大学附属第一医院 | Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用 |
| CN114214237B (zh) * | 2021-12-23 | 2023-06-16 | 南京大学 | 一种洗脱细胞表面吸附纳米颗粒的方法 |
| CN115029473B (zh) * | 2022-06-21 | 2024-06-18 | 湖北省药品监督检验研究院 | 一种基于mlpa技术对中药材桃仁与苦杏仁进行鉴别的方法 |
| CN115739182B (zh) * | 2022-11-17 | 2024-01-16 | 合肥机数量子科技有限公司 | 含单分散铁原子的过氧化物模拟酶及其制备方法和用途 |
| WO2024189098A1 (en) | 2023-03-13 | 2024-09-19 | Iomx Therapeutics Ag | Platform technology for the identification of modulators of immune effector cell function |
| CN116403649A (zh) * | 2023-03-17 | 2023-07-07 | 中山大学附属第六医院 | 一种igsf6基因在免疫治疗治疗系统中的应用 |
| WO2024197047A2 (en) * | 2023-03-20 | 2024-09-26 | The Regents Of The University Of California | Methods and materials for treating cancer |
| CN117159495A (zh) * | 2023-08-16 | 2023-12-05 | 北京大学 | 脂质纳米颗粒及其应用 |
| TWI873056B (zh) * | 2024-07-01 | 2025-02-11 | 國立成功大學 | 採用影像分割技術的胃內視鏡影像分析方法與電腦系統 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2561835A1 (en) * | 2004-03-30 | 2005-10-13 | Den Kgl. Veterinaer-Og Landbohojskole | Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors |
| US7833530B2 (en) * | 2008-05-15 | 2010-11-16 | Selexys Pharmaceuticals Corporation | Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies |
| WO2011143411A1 (en) * | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation of splenocytes in cell therapy for traumatic brain injury |
| WO2013057281A2 (en) * | 2011-10-21 | 2013-04-25 | Transgene Sa | Modulation of macrophage activation |
| WO2015077401A1 (en) * | 2013-11-20 | 2015-05-28 | Drexel University | Compositions and methods for macrophage conversion |
| US20170306042A1 (en) * | 2014-08-29 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis |
| WO2016111947A2 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| GB201611535D0 (en) * | 2016-07-01 | 2016-08-17 | King S College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
| KR20250159733A (ko) * | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
-
2019
- 2019-06-28 EP EP19825130.8A patent/EP3813881A4/en active Pending
- 2019-06-28 WO PCT/US2019/039773 patent/WO2020006385A2/en not_active Ceased
- 2019-06-28 KR KR1020217002262A patent/KR20210040948A/ko not_active Ceased
- 2019-06-28 CN CN201980056952.6A patent/CN113164589A/zh active Pending
- 2019-06-28 BR BR112020026386-9A patent/BR112020026386A2/pt unknown
- 2019-06-28 AU AU2019293600A patent/AU2019293600A1/en not_active Abandoned
- 2019-06-28 JP JP2020572903A patent/JP2021529753A/ja active Pending
- 2019-06-28 CA CA3103154A patent/CA3103154A1/en active Pending
- 2019-06-28 US US17/252,379 patent/US20210189342A1/en active Pending
- 2019-06-28 TW TW108122978A patent/TW202023629A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529753A5 (enExample) | ||
| Reiss et al. | CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial | |
| Narayan et al. | PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial | |
| Cohen et al. | B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma | |
| Sato-Kaneko et al. | Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer | |
| Luo et al. | Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept | |
| JP7428397B2 (ja) | 免疫調節性ｍ２単球を選択的に低減することによってがんを治療し、治療的免疫を増強するための方法および組成物 | |
| Fang et al. | Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications | |
| Denkert et al. | Biomarker data from the phase III KATHERINE study of adjuvant T-DM1 versus trastuzumab for residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer | |
| Lin et al. | Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications | |
| JP2023529026A5 (enExample) | ||
| Orr et al. | Phase I trial combining chemokine-targeting with loco-regional chemoimmunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity | |
| Chen et al. | SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production | |
| JP2023527410A5 (enExample) | ||
| Sorrentino et al. | CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality | |
| Han et al. | Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti–PD-L1 and lenalidomide in cutaneous T cell lymphoma | |
| JP2017527533A5 (enExample) | ||
| Wang et al. | Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis | |
| Ma et al. | Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies | |
| Wu et al. | Effects of exosomes on tumor bioregulation and diagnosis | |
| Patel et al. | Progress in personalized immunotherapy for patients with brain metastasis | |
| Hui et al. | Regulatory role of exosomes in colorectal cancer progression and potential as biomarkers | |
| Ramezani et al. | Current Understanding of the Exosomes and Their Associated Biomolecules in the Glioblastoma Biology, Clinical Treatment, and Diagnosis | |
| JP2022539038A5 (enExample) | ||
| de Oliveira Silva et al. | New avenues for the treatment of immunotherapy-resistant pancreatic cancer |